Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACO/ARO/AIO-18.1: Short-course RT vs CRT in Rectal Cancer
NCT04246684Phase 3Active, not recruiting
- Start
- Nov 2020
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, oxaliplatin, capecitabine and folinic acid in rectal cancer (2 arms). Primary endpoint: Organ preservation at 3 years. Started Nov 2020; status: active, not recruiting.
02
Drugs
fluorouraciloxaliplatincapecitabinefolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04246684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246684.